Alphabet-backed start-up Isomorphic Labs has added another name to the roster of pharma companies tapping into its AI-based drug discovery engine. Johnson & Johnson's Janssen Biotech unit is the ...
Nearly two years after Google DeepMind released an updated AlphaFold3 geared at drug discovery, its biopharmaceuticals spin-off, Isomorphic Labs, announced an even more powerful ...
The unveiling of the Isomorphic Labs Drug Design Engine (IsoDDE) represents a fundamental shift from merely predicting the shape of biological life to actively engineering its functions. While ...
Read more: US democracy under pressure, oil as a weapon, and believing in the apocalypse Swiss neutrality and the war in Iran Read more: Swiss neutrality and the war in Iran Myanmar – bringing justice ...
Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday.
Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results